About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...

Lynparza reduced the risk of death by 28% ... Also Read: After Lung Cancer Approval, AstraZeneca’s Imfinzi Goes Under FDA Priority Review For Bladder Cancer At a median follow-up of 6.1 years ...

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza were still alive six years later ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the ...

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on AZN: AstraZeneca NewsMORE Related Stocks Indices Commodities Currencies Stocks ...